It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Drug Treatment Study for Patients with Advanced Cancers

Clinical Trial Title: 
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.
Clinical Trial Protocol ID: 
15102201
Clinical Trial Investigator Name: 
Philip D. Bonomi, MD
Clinical Trial Protocol Description: 

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
  • Have documented incurable cancer with one of the following histologies: non-small cell lung cancer, malignant melanoma, renal cell cancer, triple negative breast cancer, colorectal cancer with microsatellite instability (MSI), prostate cancer, and bladder cancer.
  • Have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
  • Have at least 1 but not more than 5 prior systemic therapies for advanced/recurrent or progressing disease.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a history of severe hypersensitivity reaction to monoclonal antibodies.
  • Have any active autoimmune disease or a documented history of serious autoimmune disease within the past 5 years requiring immunosuppressive therapy.
  • Have a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.
  • Have used any investigational medication or device in the 30 days prior to screening. Use of such investigational medication during the study is also prohibited.
  • Are currently receiving denosumab and are not able to discontinue use prior to enrollment. Substitution with biphosphonates are acceptable.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Breast Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Kidney and Urinary System Disorders
Lung and Chest Tumors
Melanoma and Soft Tissue
Contact Phone: 
(312) 563-3347
Contact Name: 
Deborah Pach, RN, MSN, AOCN, CCRC